 Article
Feeds
|
OIG Audits Oncology Practices |
July 31, 2006
Previously published on September 19, 2005
Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Office of the Inspector General of the Department of Health and Human Service is required to conduct a study to determine whether physician practices, particularly large practices, in the specialties of hematology, hematology/oncology, and medical oncology are able to purchase drugs at the new reimbursement amounts, which have been set at 106% of the average sales price.
|
The views expressed in this article are solely the views of the author and not Martindale-Hubbell. This article is intended for informational purposes only and is not legal advice or a substitute for consultation with a licensed legal professional in a particular case or circumstance. |
|
|
RSS | Blogs | Site Map | Contact Us